Near-Infrared Activatable Phthalocyanine-Poly-L-Glutamic Acid Conjugate: Enhanced in Vivo Safety and Antitumor Efficacy toward an Effective Photodynamic Cancer Therapy

Molecular Pharmaceutics
Hoay Yan CheahLik Voon Kiew

Abstract

We previously developed a new zinc(II) phthalocyanine (ZnPc) derivative (Pc 1) conjugated to poly-L-glutamic acid (PGA) (1-PG) to address the limitations of ZnPc as part of an antitumor photodynamic therapy approach, which include hydrophobicity, phototoxicity, and nonselectivity in biodistribution and tumor targeting. During this study, we discovered that 1-PG possessed high near-infrared (NIR) light absorptivity (λmax = 675 nm), good singlet oxygen generation efficiency in an aqueous environment, and enhanced photocytotoxic efficacy and cancer cell uptake in vitro. In the current study, we discovered that 1-PG accumulated in 4T1 mouse mammary tumors, with a retention time of up to 48 h. Furthermore, as part of an antitumor PDT, low dose 1-PG (2 mg of Pc 1 equivalent/kg) induced a greater tumor volume reduction (-74 ± 5%) when compared to high dose ZnPc (8 mg/kg, -50 ± 12%). At higher treatment doses (8 mg of Pc 1 equivalent/kg), 1-PG reduced tumor volume maximally (-91 ± 6%) and suppressed tumor size to a minimal level for up to 15 days. The kidney, liver, and lungs of the mice treated with 1-PG (both low and high doses) were free from 4T1 tumor metastasis at the end of the study. Telemetry-spectral-echocardiography studies a...Continue Reading

References

Oct 1, 1992·Photochemistry and Photobiology·D Kessel
Jun 1, 1990·Journal of the Autonomic Nervous System·N JapundzicJ L Elghozi
Jan 1, 1989·Cancer Chemotherapy and Pharmacology·M M Tomayko, C P Reynolds
Nov 1, 1987·British Journal of Cancer·E ReddiG Jori
Apr 1, 1986·Journal of Surgical Oncology·D M EuhusF E Johnson
Jun 2, 1998·Clinical and Experimental Hypertension : CHE·N Japundzic-Zigon
Jan 1, 1997·Journal of Clinical Laser Medicine & Surgery·M S IsmailH P Berlien
Aug 31, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H GelderblomA Sparreboom
Dec 20, 2003·Journal of Controlled Release : Official Journal of the Controlled Release Society·W TanseyChun Li
Aug 22, 2006·Experimental and Molecular Pathology·Sally A DuPre', Kenneth W Hunter
Feb 21, 2007·Journal of the European Academy of Dermatology and Venereology : JEADV·P G Calzavara-PintonR Sala
Apr 29, 2008·The International Journal of Biochemistry & Cell Biology·Natalia B Rumie VittarViviana A Rivarola
Jun 27, 2009·Accounts of Chemical Research·Megan E FoxJean M J Fréchet
Aug 18, 2009·Photochemistry and Photobiology·Aisling E O'ConnorAnnette T Byrne
Nov 12, 2009·Journal of Pharmaceutical Sciences·Stepán KoudelkaJaroslav Turánek
Apr 2, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Monica CamerinDavid A Russell
Jun 22, 2011·Journal of Controlled Release : Official Journal of the Controlled Release Society·Hsueh-Lin LuPing-Shan Lai
Mar 18, 2015·Clinical Medicine Insights. Cardiology·Peter Lm Kerkhof
Dec 29, 2015·Photodiagnosis and Photodynamic Therapy·Heba AsemSherif Kandil
Sep 12, 2016·Journal of Photochemistry and Photobiology. B, Biology·Angélica M GarciaEmilio I Alarcon

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.